business

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Investing.com · Jun 6, 2026, 7:15 PM · Also reported by 2 other sources

Read full story on Investing.com → More top stories

Also covered by

STAT News STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug Healthline ‘Next-Gen’ GLP-1 Leads to 16% More Weight Loss. Is It Better Than Zepbound?

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Also covered by

More in business